SVRA

Conviction 86HealthcareScan · Fri, Jun 26, 2026

SVRA$5.89-2.32%

ResistanceSupportVol 14Insider sell

Vol MA14 2.81M

Mar 27Apr 15May 4May 20Jun 9Jun 26

Savara IncPHARMACEUTICAL PREPARATIONSwww.savarapharma.com ↗

Price5.89

Change-2.32%

Gap+0.33%

Rel volume6.88×

Avg volume2.48M

Avg $ vol13.71M

SMA 205.38

SMA 505.25

SMA 2005.14

Price vs 50+12.11%

Price vs 200+14.70%

MA stackbullish

50/200 cross—

Supertrendup · 5.12

RSI (14)66

MACD hist0.08

MACD cross—

Stoch %K / %D79 / 90

ADX (14)16

+DI / −DI28 / 12

RSI divergence—

MACD divergence—

ATR %+4.78%

ADR %5.12%

52w high6.94

52w low2.05

From 52w high-15.13%

Above 52w low+187.32%

New 52w highNo

SqueezeOff

Bollinger width22.24%

%B0.93

Donchian pos78.91%

Donchian high6.20

Donchian low4.73

AVWAP (52w high)5.64

vs AVWAP high+4.34%

AVWAP (52w low)4.96

vs AVWAP low+18.64%

OBV trendFlat

Chaikin MF (20)-0.02

Today vs 20d6.88×

Avg vol (14d)2.81M

Avg vol (20d)2.48M

Avg $ vol (20d)13.71M

Market cap—

RS 3m (vs SPY)+2.41%

RS 6m (vs SPY)-14.02%

RS line new highNo

Trend template7/8

Technical rank66.5

1 week+7.09%

1 month+13.05%

3 months+12.19%

6 months-8.54%

1 year+168.95%

YTD+4.43%

P/E-10.37

P/B7.00

P/S—

P/FCF-12.20

EPS-0.5300

Div yield0.02%

ROE-67.51%

ROA-53.62%

Debt/Eq0.17

Current13.47

EV/EBITDA-9.99

Gross margin190.26%

Net margin—

Rev growth0.00%

EPS growth-23.94%

Price target11.17

Target upside85.70%

Analyst ratingBuy

Institutional108.99%

Ent. value1.22B

Revenue0

Net income-37.28M

Gross profit2.04M

Free cash flow-101.06M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out204.93M

Employees70

ListedMon, Nov 18, 1996

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeA+

Conviction86 / 100

Pattern quality—

Tech rank66.5 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance5.48

Support4.71

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in SVRA

All disclosures →

No recent disclosed trades by Congress in SVRA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in SVRA · 2 buys · 8 sells

Insider	Side	Shares	Value	Traded	Filed
Lowrance David L Chief Financial Officer · Common Stock · 2026-06-22	Sell	394.53K	$2.2M	2026-06-22	2026-06-22
Lowrance David L Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-22	Exercise	75K	—	2026-06-22	2026-06-22
Lowrance David L Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-22	Exercise	129.35K	—	2026-06-22	2026-06-22
Lowrance David L Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-22	Exercise	56.94K	—	2026-06-22	2026-06-22
Lowrance David L Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-22	Exercise	87.65K	—	2026-06-22	2026-06-22
Lowrance David L Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-22	Exercise	218.75K	—	2026-06-22	2026-06-22
Lowrance David L Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-22	Exercise	12.5K	—	2026-06-22	2026-06-22
Lowrance David L Chief Financial Officer · Common Stock · 2026-06-22	Exercise	75K	$119K	2026-06-22	2026-06-22
Lowrance David L Chief Financial Officer · Common Stock · 2026-06-22	Tax	21.68K	$119K	2026-06-22	2026-06-22
Lowrance David L Chief Financial Officer · Common Stock · 2026-06-22	Exercise	129.35K	$159K	2026-06-22	2026-06-22

SEC filings

EDGAR filings in SVRA · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.